WO2024040156A3 - Novel cyclic gamma aapeptide pan-coronavirus inhibitor and method of treating coronavirus infection - Google Patents
Novel cyclic gamma aapeptide pan-coronavirus inhibitor and method of treating coronavirus infection Download PDFInfo
- Publication number
- WO2024040156A3 WO2024040156A3 PCT/US2023/072368 US2023072368W WO2024040156A3 WO 2024040156 A3 WO2024040156 A3 WO 2024040156A3 US 2023072368 W US2023072368 W US 2023072368W WO 2024040156 A3 WO2024040156 A3 WO 2024040156A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coronavirus
- infection
- cov
- aapeptide
- pan
- Prior art date
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title abstract 2
- 125000004122 cyclic group Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 241000288673 Chiroptera Species 0.000 abstract 1
- 241000711467 Human coronavirus 229E Species 0.000 abstract 1
- 241000482741 Human coronavirus NL63 Species 0.000 abstract 1
- 241001428935 Human coronavirus OC43 Species 0.000 abstract 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 241000315672 SARS coronavirus Species 0.000 abstract 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 239000012855 volatile organic compound Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
Abstract
A novel compound and method of treating and preventing coronavirus infection in a patient is presented. Cyclic γ AApeptide pan-coronavirus inhibitors which bind to RBD and HR1 on the spike protein were found to exhibit high proteolytic enzyme stability and good oral bioavailability. In particular, compound S-20-1 effectively inhibited infection by pseudotyped and authentic SARS-CoV-2 and pseudotyped variants of concern (VOCs), including B.1.617.2 (Delta) and B.1.529 (Omicron), as well as MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-229E, and HCoV-NL63 as well as infection of a pseudotyped SARS-related coronavirus WIV1 (SARSr-CoV-WIV1) from bats.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263371671P | 2022-08-17 | 2022-08-17 | |
| US63/371,671 | 2022-08-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024040156A2 WO2024040156A2 (en) | 2024-02-22 |
| WO2024040156A3 true WO2024040156A3 (en) | 2024-04-11 |
Family
ID=89942272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/072368 WO2024040156A2 (en) | 2022-08-17 | 2023-08-17 | Novel cyclic gamma aapeptide pan-coronavirus inhibitor and method of treating coronavirus infection |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024040156A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021181398A1 (en) * | 2020-03-11 | 2021-09-16 | Biolinerx Ltd. | Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections |
| US20220033444A1 (en) * | 2020-07-31 | 2022-02-03 | The Regents Of The University Of California | Cyclic Peptides, Methods of Synthesis, and Methods of Treatment |
| US20230042837A1 (en) * | 2021-06-16 | 2023-02-09 | University Of South Florida | Cyclic compounds for treating cancer |
-
2023
- 2023-08-17 WO PCT/US2023/072368 patent/WO2024040156A2/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021181398A1 (en) * | 2020-03-11 | 2021-09-16 | Biolinerx Ltd. | Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections |
| US20220033444A1 (en) * | 2020-07-31 | 2022-02-03 | The Regents Of The University Of California | Cyclic Peptides, Methods of Synthesis, and Methods of Treatment |
| US20230042837A1 (en) * | 2021-06-16 | 2023-02-09 | University Of South Florida | Cyclic compounds for treating cancer |
Non-Patent Citations (3)
| Title |
|---|
| HAO YAN: "Cyclic Peptidomimetics as Inhibitor for miR-155 Biogenesis", MOLECULAR PHARMACEUTICS, AMERICAN CHEMICAL SOCIETY, US, vol. 16, no. 2, 4 February 2019 (2019-02-04), US , pages 914 - 920, XP093159835, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.8b01247 * |
| HUANG BO, ZHOU LI, LIU RUOCHUAN, WANG LEI, XUE SONGYI, SHI YAN, JEONG GEON HO, JEONG IN HO, LI SIHAO, YIN JUN, CAI JIANFENG: "Activation of E6AP/UBE3A-Mediated Protein Ubiquitination and Degradation Pathways by a Cyclic γ-AA Peptide", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 65, no. 3, 10 February 2022 (2022-02-10), US , pages 2497 - 2506, XP093081300, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01922 * |
| SONGYI XUE: "A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein", CELL DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 8, no. 1, GB , XP093159837, ISSN: 2056-5968, DOI: 10.1038/s41421-022-00455-6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024040156A2 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20100093L (en) | Peptidomimetic protease inhibitors | |
| DE60219595D1 (en) | METHOD FOR TREATING DISEASES WITH MALONYL COA DECARBOXYLASE INHIBITORS | |
| WO2004043339A3 (en) | Substituted cycloalkyl p1' hepatitis c virus inhibitors | |
| MY131817A (en) | C-nitrosoaniline compounds and their blends as polymerization inhibitors | |
| AU2003299519A1 (en) | Hepatitis c virus inhibitors | |
| AU2003248535A1 (en) | Heterocyclicsulfonamide hepatitis c virus inhibitors | |
| HRP20130664T1 (en) | Heterocyclic aspartyl protease inhibitors | |
| WO2009085978A8 (en) | Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors | |
| GEP20053631B (en) | ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | |
| ATE444749T1 (en) | BENZOTHIAZOLIUM COMPOUNDS FOR USE IN METHODS OF INHIBITING NO PRODUCTION AND TNF ALPHA AND TREATING CORONAVIRUS INFECTIONS | |
| ATE447573T1 (en) | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | |
| BRPI0415288B8 (en) | pharmaceutical composition comprising crystalline 1-{[(α-isobutanoyloxyethoxy)carbonyl] aminomethyl}-1-cyclohexane acetic acid | |
| WO2005042020A3 (en) | Combinations for hcv treatment | |
| AU2003239472A1 (en) | Synthesis of benzonitriles and benzimidates | |
| WO2009127948A8 (en) | 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors | |
| AU2002341715A1 (en) | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| WO2004050620A3 (en) | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | |
| JO2605B1 (en) | Pyrrolidone derivatives as maob inhibitors | |
| UY27618A1 (en) | ESTERS HYDROXAMATE ACID N- (4-PHENYL-SUBSTITUTED) -ANTRANILIC | |
| WO2005018535A3 (en) | Compositions and methods for treatment of severe acute respiratory syndrome (sars) | |
| ATE250080T1 (en) | HCV NS3 PROTEASE INHIBITORS | |
| WO2024040156A3 (en) | Novel cyclic gamma aapeptide pan-coronavirus inhibitor and method of treating coronavirus infection | |
| EA200300272A1 (en) | NEW HINAZOLIN DERIVATIVES, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| DK1421946T3 (en) | A pharmaceutical composition for the treatment of HIV infection | |
| DE602004016841D1 (en) | USE OF 2,2,3,3, TETRAMETHYLCYCLOPROPANE CARBOXYLIC DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23855670 Country of ref document: EP Kind code of ref document: A2 |